"Genzyme geltex pharmaceuticals" Essays and Research Papers

Sort By:
Satisfactory Essays
Good Essays
Better Essays
Powerful Essays
Best Essays
Page 1 of 50 - About 500 Essays
  • Powerful Essays

    Early in 1997‚ Genzyme Corporation began negotiations with Geltex Pharmaceuticals in an attempt to launch a joint venture to market Geltex’s first product‚ RenaGel. Geltex was a young biotech research company with only two products in its pipeline‚ and they didn’t have the resources necessary to launch RenaGel on their own. Genzyme‚ on the other hand‚ was a quickly growing company that experienced revenues of $518 million in 1996. They were attracted to the joint venture with Geltex because of the

    Premium Net present value Chronic kidney disease Discounted cash flow

    • 2078 Words
    • 7 Pages
    Powerful Essays
  • Powerful Essays

    Genzyme

    • 3375 Words
    • 14 Pages

    GENZYME´S CSR DILEMMA: HOW TO PLAY ITS HANDS 1. INTRODUCTION Twenty years ago and earlier‚ with rare exceptions‚ the only corporate charity was a bit of gifting by the CEO‚ perhaps to the arts. Ten years ago‚ corporate philanthropy and volunteerism became popular as an a la carte add on. In these posts from the Clinton Global Initiative (CGI)‚ I am turning the spotlight on the avant garde of CSR: companies that make community and global problem-solving part of their business platform‚ thus

    Premium Malaria Neglected diseases Project management

    • 3375 Words
    • 14 Pages
    Powerful Essays
  • Satisfactory Essays

    Genzyme

    • 366 Words
    • 2 Pages

    Case: Genzyme Corporation Problem: High equity financing company Genzyme has a tradition to be financed with equity. High equity ratio has advantages such as low agency costs related to debt‚ lower financial stress and more flexibility for management‚ which is especially crucial for start-up companies‚ such as in the early stage of Genzyme. However‚ besides losing the tax shield from debt‚ high equity financing leads to an increasingly diffused ownership‚ which would in turn causes problems such

    Premium Stock market Information asymmetry Finance

    • 366 Words
    • 2 Pages
    Satisfactory Essays
  • Satisfactory Essays

    Genzyme Summary

    • 328 Words
    • 2 Pages

    ENT4400 – SUMMARY + REFLECTION Case study: Genzyme‚ schilling‚ chapter 6 page 105-109 Summary of the case: Genzyme was founded in 1981‚ Sanofi purchased the company in 2011. They went public in 1986‚ raising 27 million dollars. Genzyme startet as a start up Company by scientists studying genetically inherited enzyme diseases. Their strategy didn’t focus on the “blockbuster drugs” like other biotechnology companies but drugs for rare diseases. To developing a drug‚ it takes 10-14 years at

    Premium Pharmacology Pharmaceutical drug Biotechnology

    • 328 Words
    • 2 Pages
    Satisfactory Essays
  • Good Essays

    Genzyme Case Study

    • 745 Words
    • 3 Pages

    consequently there is very little competition. Big pharmaceuticals primarily focus their resources on ‘blockbuster’ drugs because there is a large market to target. Since Genzyme’s target market does not appear to be attractive for most pharmaceuticals in that regard‚ it gains significant leeway from competition by focusing on orphan drugs. Also‚ the Orphan Drug Act provides 7 years of market exclusivity which virtually eliminates competition for Genzyme for at least a while. As an orphan drug‚ there

    Premium Orphan drug Clinical trial Drug discovery

    • 745 Words
    • 3 Pages
    Good Essays
  • Good Essays

    Genzyme vs Biogen

    • 670 Words
    • 3 Pages

    Genzyme Corp. Genzyme Corporation operates as a biotechnology company worldwide. It focuses on rare genetic disease disorders‚ renal diseases‚ orthopedics‚ cancers‚ transplant and immune diseases‚ and diagnostic and predictive testing areas. Its leading drugs are Cerezyme‚ Fabrazyme‚ Myozyme‚ Aldurazyme‚ Elaprase‚ Renagel and Renvela‚ and many others. It has about 7‚000 employees. The current Chairman‚ President‚ & CEO is Henri A. Termeer. The company was founded in 1981 and is based in Cambridge

    Premium Biogen Idec Biotechnology

    • 670 Words
    • 3 Pages
    Good Essays
  • Good Essays

    Sanofi Genzyme Merger

    • 4983 Words
    • 20 Pages

    to purchase a U.S. biotech company as rumors circulate about Genzyme. 7/29/2010- Sanofi sends a private letter to Genzyme’s board of directors offering $69/share in cash. 8/22/2010- Genzyme rejects Sanofi’s offer. 8/29/2010- Sanofi goes public with its offer of $69/share. 8/30/2010- Genzyme publicly rejects Sanofi’s offer once again. 10/4/2010- Sanofi goes hostile and begins to directly solicit to Genzyme shareholders maintaining the $69/share value. The offer is

    Premium Pharmaceutical industry Stock market Stock

    • 4983 Words
    • 20 Pages
    Good Essays
  • Better Essays

    Genzyme Case Study

    • 894 Words
    • 4 Pages

    Genzyme Case Study: Table of Contents Problem Identification......................................................................................................3 Alternative Solutions.........................................................................................................4 Recommendations.............................................................................................................5

    Premium Cash flow Stock Investment

    • 894 Words
    • 4 Pages
    Better Essays
  • Powerful Essays

    Analysis of Genzyme Waterford Student Names: Fiona Mallon and Hazel Mc Partlan Course: BA (Hons) in Marketing‚ Advertising and Online Media Module: Organisational Behaviour Submission Date: 11th of April 2013 Word Count: 3218 Total Word Count: 7980 We declare that this work is our own and of the highest academic integrity. Where the work of others has been used‚ it is properly acknowledged and referenced Table of Contents 1. Brief History of Genzyme 3 2. Practice of Motivational

    Premium Maslow's hierarchy of needs

    • 7987 Words
    • 32 Pages
    Powerful Essays
  • Powerful Essays

    Play its HAND. Background Considered a leader in the biotechnology industry‚ Genzyme has come a long way since its inception as a supplier of basic chemicals and reagents in 1981. As a leader in the development of orphan drugs‚ Genzyme realized revenues of almost $4B in 2007. Greater than 30% of its revenue in 2007 is attributed to the sales of drugs that target orphan diseases‚ such as Cerezyme‚ a novel Genzyme drug used to treat Gaucher disease. Due to the lack of previous research on orphan

    Premium Orphan drug Brazil Government

    • 1889 Words
    • 8 Pages
    Powerful Essays
Previous
Page 1 2 3 4 5 6 7 8 9 50